On November 25, 2025 BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, reported the selection of two abstracts for oral presentation, three abstracts for poster presentation and one abstract for online publication at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, which will be held December 6-9, 2025, in Orlando, Florida. BostonGene will exhibit in booth #1581.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The research we are presenting highlights the critical need for advanced patient stratification in hematology. Our AI-powered tools, such as the Lymphly classifier and our B-cell-based marker provide the molecular precision required to de-risk clinical programs and ensure the right drug reaches the right patient subpopulation. This is about moving beyond conventional diagnostics to build a foundational, integrated approach for effective companion diagnostics and unified monitoring in drug studies," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Details of the presentations are below:

Oral presentations:

Abstract number: 14219
Title: Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk mantle cell lymphoma: The WINDOW-3 clinical trial
Date & time: December 7 — 5:45 PM – 6:00 PM
Location: Tangerine Ballroom F2
Speaker: Preetesh Jain, MD, DM, PhD, The University of Texas MD Anderson Cancer Center

The WINDOW-3 clinical trial evaluating acalabrutinib plus rituximab followed by brexucabtagene autoleucel CART in patients with high-risk mantle cell lymphoma (MCL) demonstrated strong efficacy and encouraging survival outcomes. BostonGene’s AI-based immunoprofiling revealed CART therapy in high-risk MCL led to drastic immune remodeling, with specific CART-cell types and memory subsets correlating with toxicity, indicating a key role in immune system monitoring for treatment-related toxicities.

Research conducted in collaboration with MD Anderson Cancer Center

Abstract number: 7242
Title: A phase 1b trial of the EZH2 inhibitor tazemetostat combined with CAR T cell therapy in B cell lymphomas
Date & time: December 8 — 5:00 PM – 5:15 PM
Location: OCCC – Tangerine Ballroom F3-4
Speaker: Samuel Yamshon, MD, Weill Cornell Medical College

Based on the premise that inhibition of EZH2 prevents T cell exhaustion and modulates T cell activity, the phase I study administered tazemetostat with CAR-T in patients with B-cell lymphoma. The combination resulted in an impressive 100% response rate with no signal of additional toxicity. BostonGene’s novel immunophenotyping is being performed to demonstrate the immune modulatory effects of combination therapy, providing mechanistic rationale for further combination approaches.

Research conducted in collaboration with Weill Cornell Medical Center

Poster presentations:

Abstract number: 1837
Title: Refining diffuse large B-cell lymphoma subtyping using Lymphly, an evidence-based classifier
Date & time: December 6 — 5:30 PM – 7:30 PM
Speaker: Nikita Kotlov, MS, BostonGene

BostonGene developed Lymphly, an AI hierarchical classifier for diffuse large B-cell lymphoma (DLBCL), to resolve genetically heterogeneous and atypical tumors often missed by existing classifications. By integrating pathway-relevant genomic alterations into a transparent framework, Lymphly distinguishes both established and emerging subtypes, including high-risk TP53+ and MYC+ groups, offering refined molecular stratification for clinical trial design, treatment selection and targeted therapy development.

Abstract number: 2692
Title: A genetic comparison of Epstein-Barr virus-associated polymorphic lymphoproliferative disorder and diffuse large B cell lymphoma
Date & time: December 6 — 5:30 PM – 7:30 PM
Speaker: Jennifer Chapman, MD, University of Miami and Sylvester Comprehensive Cancer Center

BostonGene’s multimodal platform with integrated genomic, transcriptomic and immune data was used to analyze and compare Epstein-Barr virus (EBV)-positive lymphoproliferative disorder and diffuse large B-cell lymphoma. This study underscored the complexity of EBV-driven diseases and highlighted the need for improved classification strategies, demonstrating the potential of BostonGene’s AI-powered platform to advance precision diagnostics and improve patient outcomes.

Research done in collaboration with the University of Miami Sylvester Cancer Institute

Abstract number: 12996
Title: An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma
Date & time: December 8 — 6:00 PM – 8:00 PM
Speaker: Joshua W.D. Tobin, MD, MSc, Princess Alexandra Hospital, Mater Research Institute

In collaboration with MD Anderson and several hospitals and academic institutions in Australia, BostonGene leveraged its multimodal pipeline to design a B cell-based candidate biomarker in patients with follicular lymphoma treated with bendamustine-based immunochemotherapy (ICT). Represented by centroblast (CB) scores, this biomarker identifies patients with high-grade disease who may respond to bendamustine-based ICT. Independent of and additive to pre-treatment PET, the CB score was highly prognostic suggesting a potential role for patient stratification.

Research done in collaboration with the University of Queensland

Online only

Title: Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma

BostonGene’s integrated platform, combining whole exome and RNA sequencing of tumor (CD138⁺ plasma cells) and peripheral blood samples, reproduced FISH-detectable abnormalities (e.g., del17p/TP53 deletion or t(11;14) translocations) and revealed additional mutations, structural variants and immune signatures in multiple myeloma patients, including low-tumor-content samples. By overcoming limitations of conventional FISH, BostonGene’s approach may provide a scalable solution and broader diagnostic capabilities for unified genomic and immune monitoring in clinical trials and patient care.

Research done in collaboration with the University of Miami Sylvester Cancer Institute

In addition to the poster presentations, the abstracts are published online in the November supplemental issue of Blood.

(Press release, BostonGene, NOV 25, 2025, View Source [SID1234660956])

On November 25, 2025 Agendia, Inc., a leader in precision oncology for breast cancer, reported that it will present new data demonstrating the utility of the MammaPrint 70-gene assay (MP) and BluePrint 80-gene assay (BP) genomic profiling in guiding the use of anthracycline chemotherapy in patients with hormone receptor positive, HER2-negative (HR+HER2–) early-breast cancer (EBC) at the 2025 San Antonio Breast Cancer Symposium (SABCS). The company will also present four additional posters at SABCS, which takes place December 9-12 in San Antonio, Texas. The complete list of poster presentations can be found here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The latest 3-year analysis from the prospective FLEX Study, in an update to data presented at ASCO (Free ASCO Whitepaper) 2024, confirms that patients with MP High 2 (H2), Luminal B, HR+HER2- EBC experience substantially improved invasive disease-free survival when treated with anthracycline-based chemotherapy (AC-T) compared to a regimen without anthracycline (TC). While outcomes for High 1 (H1) patients were similar between patients matched for clinical features, H2 patients saw a striking absolute invasive disease-free survival (IDFS) benefit of 10.7% with AC-T, achieving 100% 3-year IDFS. These results provide the strongest real-world evidence to date that MP can help identify the subset of HR+HER2- patients most likely to benefit from anthracycline-based therapy. Together, these findings underscore the clinical value of genomic profiling in guiding more precise and effective adjuvant treatment decisions.

"With the addition of propensity score matching, these results demonstrate how the genomic information provided by MammaPrint and BluePrint can meaningfully support adjuvant treatment decisions and therapy selection for patients with HR+HER2- early breast cancer," said William Audeh, MD, MS, Chief Medical Officer at Agendia. "By distinguishing High 2 patients – who derive substantial benefit from the addition of anthracycline to their chemotherapy regimen – from those with High 1 disease, who do not, we can better tailor therapy to each patient’s underlying tumor biology. These data further establish the value of real-world evidence and reinforces the power of precision genomics to guide more effective, individualized care and improve outcomes for patients with breast cancer."

Poster #PS2-07-03 | Dec. 10, 5:00 p.m. – 6:30 p.m. | Presenter: Joyce O’Shaughnessy

Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2– EBC

In this real-world cohort of 1,261 HR+/HER2– breast cancer patients with MP High Risk and BP Luminal B tumors from the FLEX Study, outcomes were evaluated in propensity-matched treatment groups with a median follow-up of 3.2 years. Patients with MP High Risk 2 tumors demonstrated a statistically significant improvement of 10.7% in invasive disease-free survival when treated with anthracycline-based therapy compared to TC-only regimens, while those with High 1 tumors saw no difference. These results provide real-world evidence that MP can identify the HR+/HER2- patients most likely to benefit from anthracycline-based therapy, underscoring the clinical value of genomic profiling in guiding more precise and effective adjuvant treatment decisions.

Agendia will present four additional abstracts that collectively highlight the broad clinical impact of MP and BP in optimizing treatment decisions and improving outcomes for patients with HR+/HER2– EBC, including a poster demonstrating that MP is more prognostic than histologic grade, as described below.

Poster #PS5-04-19 | Dec. 12, 12:30 p.m. – 2:00 p.m. | Presenter: Erin Cobain

70-gene signature high risk classification provides stronger prognostic value than histologic grade in HR+HER2– EBC

In this real-world analysis of 1,407 HR+HER2– EBC patients enrolled in the FLEX Study, patients with MP High 2 tumors treated with chemotherapy had significantly worse five-year distant relapse-free survival compared to High 1 tumors (86.4% vs 93.1%; p < 0.001), even after adjusting for clinicopathologic factors such as grade. Notably, grade lost independent prognostic value when corrected for MP score – highlighting the limitations of relying on histology alone and establishing MP as a superior prognostic biomarker.

"The data being presented at SABCS continue to build on the growing body of evidence supporting the expanded clinical utility of MammaPrint and BluePrint," said Mark Straley, Chief Executive Officer. "Each study adds a new dimension to how our tests inform multiple treatment decisions across the care journey for patients with early-stage breast cancer – helping more women receive the right care based on the unique biology of their tumor."

(Press release, Agendia, NOV 25, 2025, View Source [SID1234660955])

On November 25, 2025 Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, reported it has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, which achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This milestone follows Lunai’s recent peer-reviewed publication in Vaccines, a successful pre-IND meeting with the U.S. Food and Drug Administration (FDA), and growing third-party recognition from the biotechnology and scientific communities. Lunai has proposed a Phase I clinical trial evaluating its Dendritic Cell Combination Therapy (DCCT) across several high-need solid tumors, including pancreatic cancer, which currently has a five-year survival rate of just 13 percent.

"We are seeing accelerating validation from both researchers and industry partners," said David Weinstein, CEO of Lunai Bioworks. "Independent expert analysis confirms the strength of our data, while early licensing activity reflects growing confidence in this platform’s potential to unlock scalable, off-the-shelf treatments capable of reaching the patients who need them most."

In a widely circulated post on LinkedIn, Benjamin McLeod, Founder of Convey Bio and Co-Host of Bio2Bedside, highlighted the study as a potential breakthrough in cancer immunotherapy.

In humanized mouse models of pancreatic cancer—one of the most lethal and treatment-resistant tumors—Lunai’s DCCT achieved complete regression of both primary and metastatic lesions with no recurrence. These results demonstrate potent, multi-pathway immune activation.

Additionally, the late Dr. Anahid Jewett, Professor at UCLA and a leading authority in tumor immunology commented: "In our view, these results approach what could be called the ‘holy grail’ of cancer research. We observed an 80–90 percent reduction in tumor size and volume across two independent studies, with most of the remaining tissue consisting of immune cells rather than cancer cells."

Lunai is also advancing additional studies and expanding clinical reach for its DCCT platform through collaborations with leading investigators, including Dr. Steven Dubinett (UCLA) for non-small cell lung cancer and Dr. Xiaolin Zi (UC Irvine) for prostate cancer.

"Lunai’s dendritic cell approach has the potential to overcome longstanding barriers in solid tumor treatment," said Dr. Dubinett, Dean of the David Geffen School of Medicine at UCLA.

Lunai’s DCCT introduces a first-in-class, allogeneic immunotherapy designed to scale:

Lunai’s DCCT leverages the natural antigen-presenting power of dendritic cells while eliminating the cost, time, and variability associated with patient-specific manufacturing.
The DCCT is manufactured from healthy donor cells and stored ready-to-use. This off-the-shelf model reduces manufacturing timelines from weeks to days, lowering the overall treatment cost.
In humanized mouse models of pancreatic cancer, one of the most lethal and treatment-resistant tumors, DCCT achieved complete regression of both primary and metastatic lesions with no recurrence.
Lunai Bioworks is preparing for formal licensing negotiations and pre-IND activities in early 2026, advancing toward clinical development of its dendritic cell therapy platform.

(Press release, Lunai Bioworks, NOV 25, 2025, View Source [SID1234660954])

On November 25, 2025 GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, reported that it has received a milestone payment under its collaboration agreement with Mitsubishi Tanabe Pharma Corporation (MTPC). GV20 and MTPC entered into this collaboration in early 2025 to leverage GV20’s antibodies, which are specifically directed against novel tumor antigen targets discovered through GV20’s proprietary STEAD AI platform, to generate potentially first-in-class antibody-drug conjugates (ADCs).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to reach this important milestone in our partnership with MTPC," said Ying Gong, Ph.D., Chief Business Officer of GV20. "This progress reflects our shared commitment to rapidly advancing innovative ADC therapies for patients with cancer. We look forward to continuing this positive momentum."

Under the terms of the agreement, GV20 received an upfront payment and is eligible for milestone payments. MTPC received an exclusive right to negotiate a license to these antibodies during the collaboration term.

(Press release, GV20 Therapeutics, NOV 25, 2025, View Source [SID1234660953])

On November 25, 2025 Immorta Bio Inc., a scientific longevity company pioneering therapies focusing on Treating Diseases of Aging and Treating Aging as Disease, reported the publication of its international patent application PCT/WO2025184665[1], entitled "Senescence Vaccine."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The application describes Immorta Bio’s proprietary approach to stimulating the immune system to selectively eliminate senescent cells: the dysfunctional "old cells" that drive aging, inflammation, organ failure, and support tumor growth. Removing these harmful cells results in a broad anti-aging effect throughout the body while simultaneously inhibiting cancer progression, addressing two major root causes of age-related decline:

accumulation of damage, and
loss of regenerative capacity.

At the center of the patent is SenoVax, Immorta Bio’s first-in-class senolytic immunotherapy, which has demonstrated potent reduction of lung, breast, brain, skin, and pancreatic cancers in established in vivo models[2]. SenoVax is also the subject of FDA submission of IND #30745 for advanced lung cancer[3].

"SenoVax is a true first-in-class immunotherapy," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, and inventor on 26 of the company’s patent applications. "By killing senescent cells, we reduce aging biology itself while simultaneously disrupting the tumor-supportive microenvironment required for cancer survival."

Immorta Bio’s broader longevity strategy combines SenoVax with StemCellRevivify, the company’s platform for introducing young, organ-specific progenitor and mesenchymal stem cells to restore regenerative capacity. Together, the two platforms target the two fundamental drivers of aging — impaired clearance of damaged cells and loss of tissue regeneration.

"Cancer is the most prevalent disease of aging, and SenoVax allows us to attack both aging biology and tumor biology at the same time," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio. "Our clinical goal is to first establish safety and efficacy in advanced cancer patients and then expand into age-related conditions and ultimately into treating aging itself."

Immorta Bio’s preclinical work shows compelling evidence across:

multiple cancer models
aging and frailty models
organ-failure models
>100% extension of lifespan and improvement in healthspan
These results, along with the publication of this PCT application, strengthen Immorta Bio’s position as the only company developing a dual-platform solution to aging that also treats its most lethal diseases.

(Press release, Immorta Bio, NOV 25, 2025, View Source [SID1234660952])